Prestige Consumer Healthcare (PBH) Tops EPS, but the Details Tell a Less Impressive Story
Earnings beat boosted by accounting factors as organic growth guidance disappoints
Prestige Consumer Healthcare (PBH) reported non-GAAP EPS of $1.32 which topped the consensus estimates by 3 cps while revenue came in $7 million ahead of the Street estimate. However, the company cut the top end of its revenue guidance range before the quarter which takes some of the shine off the beat.
Fiscal 2025’s organic growth was only 1.2%, and PBH is guiding to only 1%-2% in fiscal 2026 which is less than inspiring in our view. More importantly, we continued to notice several accounting-related benefits that more than accounted for the earnings beat.
Let’s take a closer look at PBH’s 4Q numbers:
Summary
We saw several temporary benefits that contributed more to the quarter than the 3-cent beat including:
Bad Debt allowances dropped as a percentage of higher receivables, adding 2.4 cps y/y. Sequentially, it helped by 4c.
Inventory reserves fell as well, adding 1.5c y/y or sequentially.
PBH does not add back stock compensation to non-GAAP results. It declined y/y and added 1.9 cps to EPS.
Lower Marketing costs as a percentage of higher revenue added 4.8 cps to EPS. Marketing accrual is flat.
We have warned that PBH has considerable Goodwill and Intangible assets after many acquisitions, and was a risk for impairments. It took $12.5 million in impairments in Q4’25 and added back 19 cents after tax to adjusted EPS.
With Receivables Rising, the Allowance Continues to Fall
The lower allowance as a percentage of gross receivables y/y added 2.4 cents to EPS. The sequential drop added 4.2 cents. That is essentially the whole beat.
Within the allowance are reserves for sales returns and lower pricing, reserves for cash discounts, and bad debt reserves.
The largest part is the reserve for lower pricing and sales returns – which get used as PBH needs to introduce new product/packaging and clear the current inventory, or compete against another player who lowered prices.
Actual bad debt expense taken in fiscal 2025 was only $9,000.
The allowance is down considerably in recent years, and every 100 bps it may need to rise is a potential 3-cent EPS headwind:
The biggest issue we see with the falling allowance is the customer allowances of $14.0 million of the $16.3 million total allowance are down to 1.23% of sales. Perrigo (PRGO) is at 3.3% for similar reserves. They deal with similar customers and products. How can PBH keep cutting here?
The Inventory Reserve Also Continues to Decline
Compared sequentially or y/y – the drop in allowance percentage added 1.5 cents.
The inventory obsolescence reserve is designed to handle write-offs for product that exceeds the expiration date, slow-moving stock, or the roll-out of a new product or packaging.
This reserve used to be solidly above 4%. A 100bp increase would be a 2.2-cent headwind:
Stock Compensation Dropped as a Percentage of Sales Adding 1.9 Cents
Accrued Marketing and Marketing Expense Look Low Too
Accrued marketing dropped in Q3 and was flat in DSOs for Q4.
We would expect the seasonal surge in Q1 as new programs are planned, design work started, and advertising space reserved.
Small Impairments Have Large EPS Impacts
PBH is a slow-growth business that faces pricing pressure. Margins can move, and based on the above sources of EPS growth in Q4, it works to boost margins to offset sales pressure. Acquiring other brands and cutting costs there is another source of growth.
PBH has $527 million in Goodwill and $2.3 billion in intangible assets. That is 83% of total assets and 154% of Equity.
Those assets have to be tested for value impairment vs. management’s view of future cash flow they can earn. In Q4, PBH found that $6.6 million of indefinite-lived intangible assets were impaired and $5.9 million of finite-lived intangible assets were impaired. That $12.5 million in write-off was a very small part of those assets. But, it was a 25-cent hit (19 cents after taxes) to EPS. PBH added that back to the $1.32 it posted.
Both impairments were caused by a shift in sales toward other products. As PBH reduces retailer support and drops marketing, this seems to risk more impairments in the future.
Contact behindthenumbers@btnresearch.com for questions regarding our institutional research service.
Disclosure:
This article is intended for educational purposes and is not investment advice.
Behind the Numbers, LLC is an independent research firm structured to provide analytical research to the financial community. Behind the Numbers, LLC is not rendering investment advice based on investment portfolios and is not registered as an investment adviser in any jurisdiction. All research is based on fundamental analysis using publicly available information including SEC filed documents, company presentations, annual reports, earnings call transcripts, as well as those of competitors, customers, and suppliers. Other information sources include mass market and industry news resources. These sources are believed to be reliable, but no representation is made that they are accurate or complete, or that errors, if discovered, will be corrected. Behind the Numbers, LLC does not use company sources beyond what they have publicly written or discussed in presentations or media interviews. Behind the Numbers does not use or subscribe to expert networks. All employees are aware of this policy and adhere to it.
The authors of this report have not audited the financial statements of the companies discussed and do not represent that they are serving as independent public accountants with respect to them. They have not audited the statements and therefore do not express an opinion on them. Other CPAs, unaffiliated with Mr. Middleswart, may or may not have audited the financial statements. The authors also have not conducted a thorough "review" of the financial statements as defined by standards established by the AICPA.
This report is not intended, and shall not constitute, and nothing contained herein shall be construed as, an offer to sell or a solicitation of an offer to buy any securities referred to in this report, or a "BUY" or "SELL" recommendation. Rather, this research is intended to identify issues that investors should be aware of for them to assess their own opinion of positive or negative potential.
Behind the Numbers, LLC, its employees, its affiliated entities, and the accounts managed by them may have a position in, and from time-to-time purchase or sell any of the securities mentioned in this report. Initial positions will not be taken by any of the aforementioned parties until after the report is distributed to clients, unless otherwise disclosed. It is possible that a position could be held by Behind the Numbers, LLC, its employees, its affiliated entities, and the accounts managed by them for stocks that are mentioned in an update, or a Peek Behind the Numbers article.